The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2023

Filed:

Aug. 27, 2020
Applicants:

Merck Sharp & Dohme Llc, Rahway, NJ (US);

Ambrx, Inc., La Jolla, CA (US);

Inventors:

Paul E. Carrington, San Mateo, CA (US);

Grigori Ermakov, Santa Clara, CA (US);

Robert M. Garbaccio, Lansdale, PA (US);

Wolfgang Seghezzi, Mountain View, CA (US);

Elisabetta Bianchi, Pomezia, IT;

Federica Orvieto, Pomezia, IT;

Dennis Gately, San Diego, CA (US);

Nick Knudsen, Escondido, CA (US);

Anthony Manibusan, San Diego, CA (US);

Assignees:

Merck Sharp & Dohme LLC, Rahway, NJ (US);

Ambrx, Inc., La Jolla, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/605 (2006.01); C07K 16/26 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 3/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/605 (2013.01); A61K 47/6811 (2017.08); A61K 47/6843 (2017.08); A61P 3/10 (2018.01); C07K 16/26 (2013.01); C07K 16/2869 (2013.01); A61K 2039/505 (2013.01); C07K 2317/75 (2013.01); C07K 2319/00 (2013.01);
Abstract

Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.


Find Patent Forward Citations

Loading…